<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5341">
  <stage>Registered</stage>
  <submitdate>15/01/2016</submitdate>
  <approvaldate>15/01/2016</approvaldate>
  <nctid>NCT02659020</nctid>
  <trial_identification>
    <studytitle>A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma</studytitle>
    <scientifictitle>A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma</scientifictitle>
    <utrn />
    <trialacronym>ANNOUNCE 2</trialacronym>
    <secondaryid>I5B-MC-JGDL</secondaryid>
    <secondaryid>15839</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Soft Tissue Sarcoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Sarcoma (also see 'Bone') - soft tissue</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Olaratumab
Treatment: drugs - Gemcitabine
Treatment: drugs - Docetaxel
Treatment: drugs - Placebo

Experimental: Olaratumab + Gemcitabine + Docetaxel (Dose Escalation) - Olaratumab intravenously (IV) on day 1 and day 8 of each cycle (1 cycle = 21 days) with gemcitabine IV on day 1 and 8 and docetaxel IV on day 8. Participants may continue to receive treatment until discontinuation criteria are met.

Experimental: Olaratumab + Gemcitabine + Docetaxel - Olaratumab IV on day 1 and day 8 of each cycle (1 cycle = 21 days) with gemcitabine IV on day 1 and 8 and docetaxel IV on day 8. Participants may continue to receive treatment until discontinuation criteria are met.

Placebo Comparator: Placebo + Gemcitabine + Docetaxel - Placebo IV on day 1 and day 8 of each cycle (1 cycle = 21 days) with gemcitabine IV on day 1 and 8 and docetaxel IV on day 8. Participants may continue to receive treatment until discontinuation criteria are met.


Treatment: drugs: Olaratumab
Administered IV

Treatment: drugs: Gemcitabine
Administered IV

Treatment: drugs: Docetaxel
Administered IV

Treatment: drugs: Placebo
Administered IV

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Phase 1b: Recommended Phase 2 Dose of Olaratumab: Number of Participants with Dose Limiting Toxicity (DLT)</outcome>
      <timepoint>Cycle 1 (21 Days)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Phase 2: Overall Survival (OS) (Olaratumab-Naive)</outcome>
      <timepoint>Baseline to Date of Death Due to Any Cause (Approximately 38 Months)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Olaratumab</outcome>
      <timepoint>Post-dose on Days 1 and 8 of Cycles 1 and 3 (21 day cycles)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK: Minimum Serum Concentration (Cmin) of Olaratumab</outcome>
      <timepoint>Pre-dose on Day 8 of Cycles 1 and 3, and on Day 1 of Cycles 2 and 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK: Elimination Half-Life (T1/2) of Olaratumab</outcome>
      <timepoint>Days 8 to 21 of Cycles 1 and 3</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK: Cmax of Gemcitabine</outcome>
      <timepoint>Post-Dose on Day 8 of Cycle 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK: Area Under the Concentration-Time Curve (AUC) of Gemcitabine</outcome>
      <timepoint>Day 8 of Cycle 1, Immediately Post-Dose up to 24 Hours Post-Dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK: Cmax of Docetaxel</outcome>
      <timepoint>Post-Dose on Day 8 of Cycle 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK: AUC of Docetaxel</outcome>
      <timepoint>Day 8 of Cycle 1, Immediately Post-Dose up to 48 Hours Post-Dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>OS (Olaratumab-Pre-Treated)</outcome>
      <timepoint>Baseline to Date of Death Due to Any Cause (Approximately 38 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS)</outcome>
      <timepoint>Baseline to Objective Progression or Death from Any Cause (Approximately 38 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR])</outcome>
      <timepoint>Baseline to Objective Progression or Start of New Anti-Cancer Therapy (Approximately 38 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Control Rate (DCR): Defined as Proportion of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD)</outcome>
      <timepoint>Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Approximately 38 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to First Worsening of the Brief Pain Inventory Short Form Modified (mBPI-sf) "Worst Pain Score"</outcome>
      <timepoint>Baseline through Follow-up (Approximately 6 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Sustained Worsening of Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scale Scores</outcome>
      <timepoint>Baseline through Follow-up (Approximately 38 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health Status on the EuroQol 5-Dimension 5 Level (EQ-5D-5L)</outcome>
      <timepoint>Baseline through Follow-up (Approximately 38 Months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants with Anti-Olaratumab Antibodies</outcome>
      <timepoint>Baseline through Follow-Up (Approximately 38 Months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  The participant may have no more than 2 prior lines of systemic therapies (neoadjuvant
             and adjuvant therapies will not be considered as a prior line of therapy) for advanced
             or metastatic disease and is suitable to receive gemcitabine and docetaxel therapy.
             All previous therapies must have completed = 3 weeks (21 days) prior to first dose of
             study drug.

          -  In the Phase 2 part, prior olaratumab/doxorubicin combination therapy in 1 prior
             treatment line is allowed.

               -  Prior olaratumab therapy must have been received with doxorubicin as indicated on
                  the olaratumab label.

               -  Prior olaratumab therapy must have included at least 2 full cycles of
                  olaratumab/doxorubicin (that is, a minimum of 4 doses of olaratumab).

               -  Participants, who completed at least 2 cycles of combination
                  olaratumab/doxorubicin therapy then discontinued doxorubicin due to toxicity or
                  maximum dosing and proceeded to olaratumab monotherapy, are eligible.

               -  The most recent dose of olaratumab must have been received within 180 days of
                  randomization in this study.

          -  Availability of tumor tissue is mandatory for study eligibility. The participant must
             have consented to provide archived formalin-fixed paraffin-embedded tumor tissue or be
             subject to a pre-treatment re-biopsy of primary or metastatic tumor tissue for future
             central pathology review and translational research (if archived tissue is
             unavailable).

          -  The participant has adequate hematologic, organ, and coagulation function within 2
             weeks (14 days) prior to enrollment (Phase 1b) or randomization (Phase 2).</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  The participant is diagnosed with gastrointestinal stromal tumor (GIST) or Kaposi
             sarcoma.

          -  The participant has active central nervous system (CNS) or leptomeningeal metastasis
             (brain metastasis) at the time of enrollment (Phase 1b) or randomization (Phase 2).
             Participants with a history of a CNS metastasis previously treated with curative
             intent (for example, stereotactic radiation or surgery) that have not progressed on
             follow-up imaging, have been asymptomatic for at least 60 days, and are not receiving
             systemic corticosteroids and or/anticonvulsants, are eligible. Participants with signs
             or symptoms of neurological compromise should have appropriate radiographic imaging
             performed before enrollment (Phase 1b) /randomization (Phase 2) to rule out brain
             metastasis.

          -  The participant has received prior treatment with gemcitabine or docetaxel. Note:
             Participants previously enrolled in the I5B-MC-JGDJ (NCT02451943) or any other blinded
             study with olaratumab are not eligible to participate in this trial.

          -  The participant has electively planned or will require major surgery during the course
             of the study.

          -  Females who are pregnant or breastfeeding.

          -  The participant has an active fungal, bacterial, and/or known viral infection
             including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis
             (screening is not required).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>310</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Adelaide</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Melbourne</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3000 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Saarow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>MÃ¼nchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Regensburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szolnok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petah Tiqva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel-Aviv Jaffa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Candiolo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Merseyside</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer
      drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in
      participants with advanced soft tissue sarcoma (STS) or STS that has spread to another
      part(s) of the body.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02659020</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</name>
      <address />
      <phone>1-317-615-4559</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>